系统性硬化症的多组学图谱:从自身抗体阳性到确诊疾病
该多组学研究对健康对照、SSc特异性自身抗体阳性(SSAP)、极早期SSc诊断(VEDOSS)及局限型和弥漫型SSc患者的外周血单个核细胞转录组和血浆蛋白质组进行分析,发现从健康到确诊SSc存在连续分子梯度,SSAP和VEDOSS处于中间分子状态;固有免疫激活和I型干扰素信号在SSAP阶段即可检测到,血浆蛋白质组鉴定出血管损伤和细胞外基质重塑相关循环蛋白标志物,Connectivity Map分析优先提示JAK抑制剂和磷酸二酯酶抑制剂。
要点
- SSc相关分子异常在明显临床疾病前即可检测到。
- SSAP和VEDOSS处于健康与确诊SSc之间的中间分子状态。
- 固有免疫激活和I型干扰素信号在SSAP阶段已出现。
核心结论
- 与SSc相关的分子异常在明显临床疾病之前即可检测到。
- 多组学分析识别出跨越SSc疾病严重度谱的循环免疫、血管相关和促纤维化分子特征。
研究设计与样本
- 多组学研究,对健康对照、SSAP、VEDOSS以及局限型和弥漫型SSc患者进行外周血单个核细胞转录组学和血浆蛋白质组学分析。
主要发现
- 从健康到确诊SSc观察到连续分子梯度,SSAP和VEDOSS占据中间分子状态。
- 免疫失调尤其是固有免疫激活和I型干扰素信号在SSAP阶段可检测到,并在有序临床组中活性更高。
- 血浆蛋白质组学鉴定出跨临床组与血管损伤和细胞外基质重塑相关的循环蛋白标志物。
- Connectivity Map分析优先提示Janus激酶(JAK)抑制剂和磷酸二酯酶抑制剂为与早期疾病相关程序关联的假设生成性扰动剂。
临床怎么用
- 多组学图谱为SSc的分子特征描述和风险分层提供了框架。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Systemic sclerosis (SSc) is a progressive autoimmune disease in which pathogenic processes may begin before clinical onset. We aimed to characterise molecular alterations across the spectrum from the asymptomatic SSc-specific autoantibody-positive (SSAP) phase through very early diagnosis of SSc (VEDOSS) to established SSc using integrated multiomics profiling. METHODS: In this multiomics study, we performed peripheral blood mononuclear cell transcriptomics and plasma proteomics in healthy controls, SSAP, VEDOSS, and limited and diffuse SSc. Differential expression, expression-pattern analysis across clinical groups, and functional enrichment were conducted to evaluate group-associated molecular features. Connectivity Map (CMap) analysis was used to prioritise hypothesis-generating perturbagens linked to early and persisting transcriptional signatures. RESULTS: A continuous molecular gradient was observed from health to established SSc, with SSAP and VEDOSS occupying intermediate molecular states. Immune dysregulation, particularly innate immune activation and type I interferon signalling, was detectable at the SSAP stage and showed higher activity across the ordered clinical groups. Plasma proteomics identified circulating protein markers related to vascular injury and extracellular matrix remodelling across the clinical groups. CMap analysis prioritised Janus kinase (JAK) inhibitors and phosphodiesterase inhibitors as hypothesis-generating perturbagens linked to early disease-associated programmes. CONCLUSIONS: Molecular abnormalities associated with SSc are detectable before overt clinical disease. Multiomics profiling identifies circulating immune, vascular-associated, and profibrotic molecular features across the SSc disease severity spectrum and provides a framework for molecular characterisation and risk stratification.
引用
- Wu F, Zhao Z, Lin W, et al. Multiomics landscape of systemic sclerosis: from autoantibody-positivity to established disease. Ann Rheum Dis. 2026. PMID: 42855418. doi:10.1016/j.ard.2026.09.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。